Validation of intra- and inter-laboratory reproducibility of the Xpert HPV assay according to the international guidelines for cervical cancer screening
Tóm tắt
Từ khóa
Tài liệu tham khảo
Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30(Suppl 5):F88–99.
Meijer CJLM, Berkhof H, Heideman DA, Hesselink AT, Snijders PJF. Validation of high-risk HPV tests for primary cervical screening. J Clin Virol. 2009;46:S1–4. https://doi.org/10.1016/S1386-6532(09)00540-X .
Arbyn M, Snijders PJF, Meijer CJLM, et al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin Microbiol Infect. 2015;21:817–26.
Micalessi IM, Boulet GA, Bogers JJ, Benoy IH, Depuydt CE. High-throughput detection, genotyping and quantification of the human papillomavirus using real-time PCR. Clin Chem Lab Med. 2012;50(4):655–61.
Depuydt CE, Benoy IH, Beert JF, Criel AM, Bogers JJ, Arbyn M. Clinical validation of a type-specific real-time quantitative human papillomavirus PCR against the performance of hybrid capture 2 for the purpose of cervical cancer screening. J Clin Microbiol. 2012;50(12):4073–7.
Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 1996;6(10):986–94.
Arbyn M, Depuydt C, Benoy I, et al. VALGENT: A protocol for clinical validation of human papillomavirus assays. J Clin Virol. 2015;(Suppl 1):S14-21.
Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86(2):420–8.
Cuschieri K, Geraets D, Cuzick J, Cadman L, Moore C, Vanden Broeck D, et al. Performance of a cartridge based assay for the detection of clinically significant HPV infection - lessons from VALGENT (validation of HPV genotyping tests). J Clin Microbiol. 2016;54:2337–47.